Promethera Biosciences

ImmunoBiochem has announced its plans to form a partnership with Centre for Commercialization of Antibodies and Biologics (CCAB) to develop and engineer synthetic antibody technologies and advance its antibody-drug conjugate (ADC) technology platform.

The agreement enables ImmunoBiochem to develop human therapeutics antibodies against its lead cancer candidate and engineer them into ADCs.

It also further enables CCAB to grant licensing options to ImmunoBiochem for its new intellectual property to support the latter to move from proof of concept to developing ready therapeutic drugs.

Promethera Biosciences is set to advance its therapeutic pipeline for a wide range of liver diseases, including large indications through the acquisition of Cytonet’s assets in exchange of its shares.

A US facility of Cytonet in Durham, NC, will add to Promethera’s sites as a result of the transaction.

The 18-person Durham team working on liver cell therapy, cell therapy product manufacturing and liver sourcing, will join Promethera, along with a team of seven from Germany, to assist the filing of new drug submissions for Heparesc with Health Canada.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Heparesc is meant to treat inherited urea cycle defect (UCD) in newborns and young children.

"The acquisition enables Promethera to expand its management and develop its pipeline therapies."

The acquisition enables Promethera to expand its management and develop its pipeline therapies.

Gemphire Therapeutics intends to sell its common stock by the placement of shares in an initial public offering (IPO).

It has filed a registration statement with the US Securities and Exchange Commission for the same.

The company plans to use the funds for investing partly in the developmental costs of clinical trials, pre-clinical trials, manufacturing of gemcabene and also costs associated with its EOP2 meeting with the US FDA.

A portion of the proceeds will also be used for general corporate purposes, meeting working capital requirements and other costs.

Recipharm, a contract development and manufacturing organisation, has announced a shares offering, the proceeds of which will be used to fund its planned acquisition of certain businesses of Kemwell Biopharma.

The offering will raise $104.46m.

Image: The acquisition enables Promethera to expand its management and develop its pipeline therapies. Photo: courtesy of Promethera.